Literature DB >> 29183886

The impact of age, NPM1mut, and FLT3ITD allelic ratio in patients with acute myeloid leukemia.

Jasmin Straube1, Victoria Y Ling1, Geoffrey R Hill1,2,3, Steven W Lane1,2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29183886     DOI： 10.1182/blood-2017-09-807438

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  8 in total

1.  FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical?

Authors:  Mark J Levis; Yi-Bin Chen; Mehdi Hamadani; Mary M Horowitz; Richard J Jones
Journal:  J Clin Oncol       Date:  2019-04-29       Impact factor: 44.544

2.  Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantation.

Authors:  Juliane Grimm; Madlen Jentzsch; Marius Bill; Karoline Goldmann; Julia Schulz; Dietger Niederwieser; Uwe Platzbecker; Sebastian Schwind
Journal:  Blood Adv       Date:  2020-08-25

3.  The Impact of DNMT3A Status on NPM1 MRD Predictive Value and Survival in Elderly AML Patients Treated Intensively.

Authors:  Heiblig Maël; Duployez Nicolas; Marceau Alice; Lebon Delphine; Goursaud Laure; Plantier Isabelle; Stalnikiewich Laure; Cambier Nathalie; Balsat Marie; Fossard Gaëlle; Labussière-Wallet Hélène; Barraco Fiorenza; Ducastelle-Lepretre Sophie; Sujobert Pierre; Huet Sarah; Hayette Sandrine; Ghesquières Hervé; Thomas Xavier; Preudhomme Claude
Journal:  Cancers (Basel)       Date:  2021-04-29       Impact factor: 6.639

4.  CD123 Is Consistently Expressed on NPM1-Mutated AML Cells.

Authors:  Vincenzo Maria Perriello; Ilaria Gionfriddo; Roberta Rossi; Francesca Milano; Federica Mezzasoma; Andrea Marra; Orietta Spinelli; Alessandro Rambaldi; Ombretta Annibali; Giuseppe Avvisati; Francesco Di Raimondo; Stefano Ascani; Brunangelo Falini; Maria Paola Martelli; Lorenzo Brunetti
Journal:  Cancers (Basel)       Date:  2021-01-28       Impact factor: 6.639

5.  Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field.

Authors:  Brunangelo Falini; Sofia Sciabolacci; Lorenza Falini; Lorenzo Brunetti; Maria Paola Martelli
Journal:  Leukemia       Date:  2021-04-20       Impact factor: 12.883

Review 6.  NPM1-Mutated Myeloid Neoplasms with <20% Blasts: A Really Distinct Clinico-Pathologic Entity?

Authors:  Fabio Forghieri; Vincenzo Nasillo; Ambra Paolini; Francesca Bettelli; Valeria Pioli; Davide Giusti; Andrea Gilioli; Corrado Colasante; Gloria Acquaviva; Giovanni Riva; Patrizia Barozzi; Rossana Maffei; Leonardo Potenza; Roberto Marasca; Claudio Fozza; Enrico Tagliafico; Tommaso Trenti; Patrizia Comoli; Giuseppe Longo; Mario Luppi
Journal:  Int J Mol Sci       Date:  2020-11-26       Impact factor: 5.923

7.  Not all patients with AML over 60 years of age should be offered early allogeneic stem cell transplantation.

Authors:  H Joachim Deeg
Journal:  Blood Adv       Date:  2022-03-08

8.  Better the cure you know: why patients with AML ≥60 years of age should be offered early allogeneic stem cell transplantation.

Authors:  Siok-Keen Tey; Steven W Lane
Journal:  Blood Adv       Date:  2022-03-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.